{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:43:05Z","timestamp":1792226585200,"version":"4.4.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clbc.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T13:16:54Z","timestamp":1619443014000},"page":"e618-e630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Bone-modifying Agents (BMAs) in Breast Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Charles L.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2021.04.009_bib0001","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clbc.2021.04.009_bib0002","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0003","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bcp.13852","article-title":"Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss","volume":"85","author":"Dionisio","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0004","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clbc.2021.04.009_bib0005","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0006","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1758834011412656","article-title":"Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion","volume":"3","author":"Steger","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0007","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","article-title":"Denosumab: A Review in Postmenopausal Osteoporosis","volume":"35","author":"Deeks","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clbc.2021.04.009_bib0008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12609-018-0295-6","article-title":"Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer","volume":"10","author":"Heeke","year":"2018","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.clbc.2021.04.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115501","article-title":"On the pharmacological evaluation of bisphosphonates in humans","volume":"139","author":"Cremers","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.clbc.2021.04.009_bib0010","article-title":"Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)","volume":"0","author":"Shapiro","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clbc.2021.04.009_bib0011","unstructured":"Foundation IO: What is osteoporois?, 2020 www.https:\/\/www. osteoporosis. foundation."},{"key":"10.1016\/j.clbc.2021.04.009_bib0012","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer Survivorship","volume":"379","author":"Shapiro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0013","series-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","year":"2004"},{"key":"10.1016\/j.clbc.2021.04.009_bib0014","article-title":"Control of Bone Matrix Properties by Osteocytes","volume":"11","author":"Creecy","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clbc.2021.04.009_bib0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2021.04.009_bib0016","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ecl.2015.05.002","article-title":"Bone Health and Osteoporosis","volume":"44","author":"Lupsa","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.clbc.2021.04.009_bib0017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bone.2016.03.016","article-title":"Estrogen receptors alpha and beta in bone","volume":"87","author":"Khalid","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.clbc.2021.04.009_bib0018","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.186.4.489","article-title":"Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts","volume":"186","author":"Kameda","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0019","first-page":"3128","article-title":"The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone","volume":"82","author":"Tomkinson","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clbc.2021.04.009_bib0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1196\/annals.1402.068","article-title":"T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis","volume":"1116","author":"Weitzmann","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clbc.2021.04.009_bib0021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2008.02.017","article-title":"Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis","volume":"43","author":"D'Amelio","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.clbc.2021.04.009_bib0022","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.seminoncol.2003.08.028","article-title":"Osteopenia and osteoporosis in women with breast cancer","volume":"30","author":"Ramaswamy","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-009-1034-7","article-title":"The potential impact of new National Osteoporosis Foundation guidance on treatment patterns","volume":"21","author":"Dawson-Hughes","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0024","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/jbmr.3698","article-title":"Meta-Analysis of Genomewide Association Studies Reveals Genetic Variants for Hip Bone Geometry","volume":"34","author":"Hsu","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41588-018-0302-x","article-title":"An atlas of genetic influences on osteoporosis in humans and mice","volume":"51","author":"Morris","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.clbc.2021.04.009_bib0026","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1210\/me.2014-1147","article-title":"Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics","volume":"28","author":"Liu","year":"2014","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12916-015-0373-9","article-title":"Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis","volume":"13","author":"Artigalas","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0028","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/jbmr.2849","article-title":"Objectively Verified Parental Hip Fracture Is an Independent Risk Factor for Fracture: a Linkage Analysis of 478,792 Parents and 261,705 Offspring","volume":"31","author":"Yang","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0029","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the managment of glucocorticoid-induced osteoporsis","volume":"23","author":"lekamwaan","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0030","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00198-018-4473-1","article-title":"Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"29","author":"Jin","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0031","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00198-014-2879-y","article-title":"Alcohol consumption and hip fracture risk","volume":"26","author":"Zhang","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0032","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clbc.2021.04.009_bib0033","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0034","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0035","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1359\/jbmr.2003.18.5.900","article-title":"Fracture risk after bilateral oophorectomy in elderly women","volume":"18","author":"Melton","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0036","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000333.pub2","article-title":"Exercise for preventing and treating osteoporosis in postmenopausal women","author":"Howe","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2021.04.009_bib0038","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11764-017-0622-3","article-title":"Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses","volume":"11","author":"Fornusek","year":"2017","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.clbc.2021.04.009_bib0039","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.288.15.1889","article-title":"Clinical use of bone densitometry: scientific review","volume":"288","author":"Cummings","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2021.04.009_bib0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/jwh.2013.4611","article-title":"Osteoporosis prevention, screening, and treatment: a review","volume":"23","author":"Kling","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.clbc.2021.04.009_bib0041","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jbo.2016.10.004","article-title":"Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score","volume":"7","author":"Mariotti","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0042","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01696","article-title":"Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0043","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0044","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0045","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0046","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0047","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Dowsett","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2021.04.009_bib0048","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.2165\/0003495-200868180-00005","article-title":"Aromatase inhibitor-associated bone loss: clinical considerations","volume":"68","author":"Pant","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clbc.2021.04.009_bib0049","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2021.04.009_bib0050","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0051","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2021.04.009_bib0052","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2021.04.009_bib0053","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"10.1016\/j.clbc.2021.04.009_bib0054","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/13697137.2015.1100383","article-title":"Management of bone disease in women after breast cancer","volume":"18","author":"Milat","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2021.04.009_bib0055","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/archinte.1994.00420220081009","article-title":"Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years","volume":"154","author":"Love","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0056","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0057","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2021.04.009_bib0058","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2021.04.009_bib0059","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.fertnstert.2011.10.040","article-title":"Impact of cancer therapies on ovarian reserve","volume":"97","author":"Gracia","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clbc.2021.04.009_bib0060","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nrc1992","article-title":"Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants","volume":"6","author":"Stearns","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0061","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-012-2170-x","article-title":"Metformin and breast cancer risk: a meta-analysis and critical literature review","volume":"135","author":"Col","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2021.04.009_bib0062","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.ejca.2007.04.006","article-title":"Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI","volume":"43","author":"Partridge","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0063","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/WHE.09.42","article-title":"Effect of bilateral oophorectomy on women's long-term health","volume":"5","author":"Parker","year":"2009","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.clbc.2021.04.009_bib0064","doi-asserted-by":"crossref","first-page":"h4580","DOI":"10.1136\/bmj.h4580","article-title":"Calcium intake and risk of fracture: systematic review","volume":"351","author":"Bolland","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2021.04.009_bib0065","article-title":"Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men","author":"Avenell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2021.04.009_bib0066","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00132-017-3446-y","article-title":"The effect of vitamin D and calcium supplementation on falls in older adults: A systematic review and meta-analysis","volume":"46","author":"Wu","year":"2017","journal-title":"Orthopade"},{"key":"10.1016\/j.clbc.2021.04.009_bib0067","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ecl.2017.07.004","article-title":"Effect of Vitamin D on Falls and Physical Performance","volume":"46","author":"Dhaliwal","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.clbc.2021.04.009_bib0068","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nutres.2010.12.001","article-title":"Prevalence and correlates of vitamin D deficiency in US adults","volume":"31","author":"Forrest","year":"2011","journal-title":"Nutr Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0069","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/jwh.2011.3009","article-title":"Vitamin d deficiency in postmenopausal breast cancer survivors","volume":"21","author":"Friedman","year":"2012","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.clbc.2021.04.009_bib0070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.maturitas.2010.03.012","article-title":"Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer","volume":"66","author":"Nogues","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2021.04.009_bib0071","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.critrevonc.2013.07.002","article-title":"Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy","volume":"88","author":"Datta","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0073","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.maturitas.2016.10.007","article-title":"Osteoporosis management in patients with breast cancer: EMAS position statement","volume":"95","author":"Tremollieres","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2021.04.009_bib0074","doi-asserted-by":"crossref","first-page":"411","DOI":"10.21037\/gs.2018.07.05","article-title":"Osteoporosis and musculoskeletal complications related to therapy of breast cancer","volume":"7","author":"Suskin","year":"2018","journal-title":"Gland Surg"},{"key":"10.1016\/j.clbc.2021.04.009_bib0075","first-page":"1","article-title":"Risk factors for Incident fracture in patients with breast cancer treated with aromatase inhibitors: B-ABLE cohort","author":"Garcia-Giralt","year":"2020","journal-title":"Rev Osteoporos Metab Miner"},{"key":"10.1016\/j.clbc.2021.04.009_bib0076","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1759720X14564562","article-title":"Fragility fracture: recent developments in risk assessment","volume":"7","author":"Aspray","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.clbc.2021.04.009_bib0077","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2018.6537","article-title":"Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"319","author":"Viswanathan","year":"2018","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.clbc.2021.04.009_bib0078","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1007\/s00198-010-1253-y","article-title":"Development and use of FRAX in osteoporosis","volume":"21","author":"Kanis","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0079","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/jbmr.3726","article-title":"Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study","volume":"34","author":"Leslie","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0080","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1634\/theoncologist.2019-0149","article-title":"Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study","volume":"24","author":"Leslie","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2021.04.009_bib0081","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1056\/NEJM200106283442607","article-title":"Side effects of adjuvant treatment of breast cancer","volume":"344","author":"Shapiro","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0082","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone Health in Cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Cole m","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0083","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0084","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/bonekey.2015.60","article-title":"Cancer Treatment-Induced Bone Loss in women with breast cancer","volume":"4","author":"Hadji","year":"2015","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.clbc.2021.04.009_bib0085","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0086","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0087","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0088","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0089","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2021.04.009_bib0091","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","article-title":"Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study","volume":"94","author":"Wilson","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0092","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","article-title":"Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis","volume":"24","author":"Freemantle","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0093","first-page":"S1","article-title":"Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report","volume":"18","author":"Levis","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clbc.2021.04.009_bib0094","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41413-020-00105-1","article-title":"Molecular mechanisms and clinical management of cancer bone metastasis","volume":"8","author":"Wang","year":"2020","journal-title":"Bone Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semcancer.2020.01.004","article-title":"Breast cancer metastasis to bone: From epithelial to mesenchymal transition to breast osteoblast-like cells","volume":"72","author":"Scimeca","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0096","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tranon.2019.10.012","article-title":"Bone Metastasis: Current State of Play","volume":"13","author":"Turpin","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0097","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00223-017-0362-4","article-title":"Hallmarks of Bone Metastasis","volume":"102","author":"Johnson","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0098","doi-asserted-by":"crossref","first-page":"98","DOI":"10.23736\/S1824-4785.19.03203-5","article-title":"Bone metastases in the era of targeted treatments: insights from molecular biology","volume":"63","author":"Dewulf","year":"2019","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2021.04.009_bib0099","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0100","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.567844","article-title":"Osteocytes and Bone Metastasis","volume":"11","author":"Riquelme","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clbc.2021.04.009_bib0102","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc865","article-title":"Dissemination and growth of cancer cells in metastatic sites","volume":"2","author":"Chambers","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0103","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1158\/1078-0432.CCR-13-1590","article-title":"Molecular mechanisms of bone metastasis and associated muscle weakness","volume":"20","author":"Waning","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0104","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a037556","article-title":"Cancer Cell Dormancy in Metastasis","volume":"10","author":"Summers","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0105","first-page":"e1156","article-title":"Tumor dormancy in bone","volume":"3","author":"Mayhew","year":"2020","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.clbc.2021.04.009_bib0106","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0107","doi-asserted-by":"crossref","first-page":"e10186","DOI":"10.1002\/jbm4.10186","article-title":"The Emerging Role of Osteocytes in Cancer in Bone","volume":"3","author":"Atkinson","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.clbc.2021.04.009_bib0108","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bonekey.2015.57","article-title":"Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors","volume":"4","author":"Shiozawa","year":"2015","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.clbc.2021.04.009_bib0109","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/bph.14836","article-title":"Non-coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance","volume":"172","author":"Puppo","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11914-019-00510-4","article-title":"MicroRNAs in Bone Metastasis","volume":"17","author":"Hesse","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.clbc.2021.04.009_bib0111","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2781","article-title":"Breast cancer metastasis to the bone: mechanisms of bone loss","volume":"12","author":"Chen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0112","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091415","article-title":"Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?","volume":"17","author":"Casimiro","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2021.04.009_bib0113","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00018-016-2425-5","article-title":"Wnt signaling and cellular metabolism in osteoblasts","volume":"74","author":"Karner","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clbc.2021.04.009_bib0114","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12885-015-1528-y","article-title":"The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer","volume":"15","author":"Brockton","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0117","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0118","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0119","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.clbc.2021.04.009_bib0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","article-title":"The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate","volume":"20","author":"Lipton","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clbc.2021.04.009_bib0121","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0122","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0123","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2021.04.009_bib0124","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0125","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0126","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/13696998.2019.1651122","article-title":"Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"23","author":"Stopeck","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.clbc.2021.04.009_bib0128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10198-018-1011-1","article-title":"Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review","volume":"20","author":"Matuoka","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clbc.2021.04.009_bib0129","first-page":"1785","article-title":"Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases","volume":"21","author":"Koo","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/ejhpharm-2012-000235","article-title":"Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland","volume":"20","author":"Lothgren","year":"2013","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"10.1016\/j.clbc.2021.04.009_bib0131","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clbc.2012.04.001","article-title":"Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases","volume":"12","author":"Xie","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0132","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.clinthera.2012.04.008","article-title":"Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer","volume":"34","author":"Snedecor","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clbc.2021.04.009_bib0133","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-Related Osteonecrosis of the Jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0134","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0135","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100259","article-title":"Atypical femoral fractures from bisphosphonate in cancer patients - Review","volume":"18","author":"Lockwood","year":"2019","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0137","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12603-015-0652-3","article-title":"Epidemiology and Postoperative Outcomes of Atypical Femoral Fractures in Older Adults: A Systematic Review","volume":"21","author":"Khow","year":"2017","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.clbc.2021.04.009_bib0138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0139","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1245\/s10434-012-2814-4","article-title":"Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study","volume":"20","author":"Domschke","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0141","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2407-13-480","article-title":"Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial","volume":"13","author":"Banys","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0142","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","article-title":"Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis","volume":"25","author":"Canon","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clbc.2021.04.009_bib0143","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/jcm3020521","article-title":"Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives","volume":"3","author":"Beuzeboc","year":"2014","journal-title":"J Clin Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0144","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0145","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0146","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0147","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0148","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2021.04.009_bib0149","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2021.04.009_bib0150","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0151","doi-asserted-by":"crossref","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN Guidelines Insights: Breast Cancer, Version 1.2017","volume":"15","author":"Gradishar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2021.04.009_bib0152","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000499931","article-title":"St. Gallen\/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment","volume":"14","author":"Balic","year":"2019","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.clbc.2021.04.009_bib0153","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0154","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0156","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0157","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0158","article-title":"Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness","volume":"5","author":"Hesse","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clbc.2021.04.009_bib0159","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2021.04.009_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-018-0036-5","article-title":"Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis","volume":"7","author":"Nakai","year":"2019","journal-title":"Bone Res"},{"key":"10.1016\/j.clbc.2021.04.009_bib0161","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fcell.2020.00325","article-title":"Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0162","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00198-010-1480-2","article-title":"Mortality rates after incident non-traumatic fractures in older men and women","volume":"22","author":"Morin","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clbc.2021.04.009_bib0163","first-page":"197","article-title":"Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience","volume":"26","author":"Tremblay","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2021.04.009_bib0164","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical Practice. Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2021.04.009_bib0165","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jocd.2019.07.003","article-title":"Detection of Atypical Femur Fractures","volume":"22","author":"Cheung","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.clbc.2021.04.009_bib0166","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.04.009_bib0167","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:23:03Z","timestamp":1761513783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820921000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":167,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1526820921000872"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2021.04.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone-modifying Agents (BMAs) in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}